Trial · NCT03016715
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
NCT03016715, Phase 2, Unknown, Premier Specialists, Australia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study. Trials, record NCT03016715. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03016715
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
- NCT number
- NCT03016715
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 8 participants, estimated
- Lead sponsor
- Premier Specialists, Australia
- Conditions
- Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
- Interventions
- Sirolimus 2%, Vehicle
- First posted
- 2017-01-10
- Last updated
- 2017-10-24
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Foot Health Status Questionnaire | Change from Baseline to End of Treatment completion at 32 Week | Foot function utilizing the validated Foot Health Status Questionnaire (FHSQ) as a change from baseline to the end of each treatment. |
| Secondary | FitBit® / pedometer | Baseline and through study treatment completion at 32-weeks] | |
| Secondary | Plantar defect size using 3D Photography | Change in total defect area from Baseline, clinical visits at Week 4, Week 12, Week 16, Week 28, through study treatment completion at 32-weeks | Plantar defect size measurements using 3D photography (% change in total defect area) from baseline to the end of each treatment. |
| Secondary | Child Dermatological Quality of Life Questionnaire | Baseline through study treatment completion at 32 weeks | |
| Secondary | The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale | Baseline and through study treatment completion at 32-weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03016715
GET https://conductscience.org/api/trials/v1/NCT03016715/registered